Soluble urokinase plasminogen activator receptor level is an independent predictor of the presence and severity of coronary artery disease and of future adverse events

Journal of the American Heart Association

Volumn 3, Issue 5, 2014, Pages

  Eapen, Danny J ^a   Manocha, Pankaj ^a   Ghasemzadeh, Nima ^a   Patel, Riyaz S ^a,b   Kassem, Hatem Al ^a   Hammadah, Muhammad ^a   Veledar, Emir ^a   Le, Ngoc Anh ^a   Pielak, Tomasz ^c   Thorball, Christian W ^c   Velegraki, Aristea ^d   Kremastinos, Dimitrios T ^d   Lerakis, Stamatios ^a,d   Sperling, Laurence ^a   Quyyumi, Arshed A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c Mental Health Services CPH   (Denmark)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Biomarker; C reactive protein; Cardiovascular outcomes; Coronary heart disease; Inflammation

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CLOPIDOGREL; UROKINASE RECEPTOR; AUTACOID;

ADULT; ADVERSE OUTCOME; ANGIOCARDIOGRAPHY; ARTICLE; BODY MASS; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DIABETES MELLITUS; DISEASE SEVERITY; EVENT FREE SURVIVAL; FEMALE; GENSINI SCORE; HEART DEATH; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; BLOOD; COHORT ANALYSIS; CORONARY ANGIOGRAPHY; MORTALITY; PREDICTIVE VALUE; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RADIOGRAPHY; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SOLUBILITY; SURVIVAL RATE;

COHORT STUDIES; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MALE; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SOLUBILITY; SURVIVAL RATE;

EID: 84930519930     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.114.001118     Document Type: Article

References (25)

1. Fuhrman B. The urokinase system in the pathogenesis of atherosclerosis. Atherosclerosis. 2012;222:8-14.
2. Edsfeldt A, Nitulescu M, Grufman H, Gronberg C, Persson A, Nilsson M, Persson M, Bjorkbacka H, Goncalves I. Soluble urokinase plasminogen activator receptor is associated with inflammation in the vulnerable human atherosclerotic plaque. Stroke. 2012;43:3305-3312.
3. Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen TW, Langkilde A, Petersen J, Pielak T, Moller LN, Jeppesen J, Lyngbaek S, Fenger M, Olsen MH, Hildebrandt PR, Borch-Johnsen K, Jorgensen T, Haugaard SB. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med. 2010;268:296-308.
4. Lyngbaek S, Marott JL, Sehestedt T, Hansen TW, Olsen MH, Andersen O, Linneberg A, Haugaard SB, Eugen-Olsen J, Hansen PR, Jeppesen J. Cardiovascular risk prediction in the general population with use of suPAR, crp, and framingham risk score. Int J Cardiol. 2013;167:2904-2911.
5. Lyngbaek S, Marott JL, Moller DV, Christiansen M, Iversen KK, Clemmensen PM, Eugen-Olsen J, Jeppesen JL, Hansen PR. Usefulness of soluble urokinase plasminogen activator receptor to predict repeat myocardial infarction and mortality in patients with st-segment elevation myocardial infarction undergoing primary percutaneous intervention. Am J Cardiol. 2012;110:1756-1763.
6. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Thygesen K, Alpert JS, White HD, Jaffe AS, Katus HA, Apple FS, Lindahl B, Morrow DA, Chaitman BR, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow JJ, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasche P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Morais J, Aguiar C, Almahmeed W, Arnar DO, Barili F, Bloch KD, Bolger AF, Botker HE, Bozkurt B, Bugiardini R, Cannon C, de Lemos J, Eberli FR, Escobar E, Hlatky M, James S, Kern KB, Moliterno DJ, Mueller C, Neskovic AN, Pieske BM, Schulman SP, Storey RF, Taubert KA, Vranckx P, Wagner DR. Third universal definition of myocardial infarction. J Am Coll Cardiol. 2012;60:1581-1598.
7. Austen WG, Edwards JE, Frye RL, Gensini GG, Gott VL, Griffith LS, McGoon DC, Murphy ML, Roe BB. A reporting system on patients evaluated for coronary artery disease. Report of the ad hoc committee for grading of coronary artery disease, council on cardiovascular surgery, american heart association. Circulation. 1975;51:5-40.
8. Gensini G. Coronary Arteriography. New York, NY: Futura Publishing Co; 1975.
9. Jeppesen J, Hansen TW, Olsen MH, Rasmussen S, Ibsen H, Torp-Pedersen C, Hildebrandt PR, Madsbad S. C-reactive protein, insulin resistance and risk of cardiovascular disease: a population-based study. Eur J Cardiovasc Prev Rehabil. 2008;15:594-598.
10. Andersen O, Eugen-Olsen J, Kofoed K, Iversen J, Haugaard SB. Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in hiv-infected patients receiving highly active antiretroviral therapy. J Med Virol. 2008;80:209-216.
11. Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3:32-35.
12. Pencina MJ, D'Agostino RB, D'Agostino RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the roc curve to reclassification and beyond. Stat Med. 2008;27:157-172.
13. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci. 2000;57:25-40.
14. Waltz DA, Fujita RM, Yang X, Natkin L, Zhuo S, Gerard CJ, Rosenberg S, Chapman HA. Nonproteolytic role for the urokinase receptor in cellular migration in vivo. Am J Respir Cell Mol Biol. 2000;22:316-322.
15. Kofoed K, Schneider UV, Scheel T, Andersen O, Eugen-Olsen J. Development and validation of a multiplex add-on assay for sepsis biomarkers using xmap technology. Clin Chem. 2006;52:1284-1293.
16. Riisbro R, Christensen IJ, Hogdall C, Brunner N, Hogdall E. Soluble urokinase plasminogen activator receptor measurements: influence of sample handling. Int J Biol Markers. 2001;16:233-239.
17. Thuno M, Macho B, Eugen-Olsen J. SuPAR: the molecular crystal ball. Dis Markers. 2009;27:157-172.
18. Suberviola B, Castellanos-Ortega A, Ruiz Ruiz A, Lopez-Hoyos M, Santibanez M. Hospital mortality prognostication in sepsis using the new biomarkers suPAR and proadm in a single determination on icu admission. Intensive Care Med. 2013;39:1945-1952.
19. Asciutto G, Edsfeldt A, Dias NV, Nilsson J, Prehn C, Adamski J, Goncalves I. Treatment with beta-blockers is associated with lower levels of lp-pla2 and suPAR in carotid plaques. Cardiovas Pathol. 2013;32:438-443.
20. Kjellman A, Akre O, Gustafsson O, Hoyer-Hansen G, Lilja H, Norming U, Piironen T, Tornblom M. Soluble urokinase plasminogen activator receptor as a prognostic marker in men participating in prostate cancer screening. J Intern Med. 2011;269:299-305.
21. Persson M, Engstrom G, Bjorkbacka H, Hedblad B. Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of cvd. Results from the malmo diet and cancer study. Atherosclerosis. 2012;220:502-505.
22. St-Pierre AC, Cantin B, Bergeron J, Pirro M, Dagenais GR, Despres JP, Lamarche B. Inflammatory markers and long-term risk of ischemic heart disease in men a 13-year follow-up of the quebec cardiovascular study. Atherosclerosis. 2005;182:315-321.
23. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, Jacques PF, Rifai N, Selhub J, Robins SJ, Benjamin EJ, D'Agostino RB, Vasan RS. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355:2631-2639.
24. Kim HC, Greenland P, Rossouw JE, Manson JE, Cochrane BB, Lasser NL, Limacher MC, Lloyd-Jones DM, Margolis KL, Robinson JG. Multimarker prediction of coronary heart disease risk: the women's health initiative. J Am Coll Cardiol. 2010;55:2080-2091
25. Eapen DJ, Manocha P, Patel RS, Hammadah M, Veledar E, Wassel C, Nanjundappa RA, Sikora S, Malayter D, Wilson PW, Sperling L, Quyyumi AA, Epstein SE. Aggregate risk score based on markers of inflammation, cell stress, and coagulation is an independent predictor of adverse cardiovascular outcomes. J Am Coll Cardiol. 2013;62:329-337.